185 related articles for article (PubMed ID: 30425091)
21. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
[TBL] [Abstract][Full Text] [Related]
22. Bone metastases in gastric cancer follow a RANKL-independent mechanism.
D'Amico L; Satolli MA; Mecca C; Castiglione A; Ceccarelli M; D'Amelio P; Garino M; De Giuli M; Sandrucci S; Ferracini R; Roato I
Oncol Rep; 2013 Apr; 29(4):1453-8. PubMed ID: 23404437
[TBL] [Abstract][Full Text] [Related]
23. Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Odén L; Akbari M; Zaman T; Singer CF; Sun P; Narod SA; Salmena L; Kotsopoulos J
Oncotarget; 2016 Dec; 7(52):86687-86694. PubMed ID: 27893411
[TBL] [Abstract][Full Text] [Related]
24. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
Sarink D; Schock H; Johnson T; Overvad K; Holm M; Tjønneland A; Boutron-Ruault MC; His M; Kvaskoff M; Boeing H; Lagiou P; Papatesta EM; Trichopoulou A; Palli D; Pala V; Mattiello A; Tumino R; Sacerdote C; Bueno-de-Mesquita HBA; van Gils CH; Peeters PH; Weiderpass E; Agudo A; Sánchez MJ; Chirlaque MD; Ardanaz E; Amiano P; Khaw KT; Travis R; Dossus L; Gunter M; Rinaldi S; Merritt M; Riboli E; Kaaks R; Fortner RT
Cancer Prev Res (Phila); 2017 Sep; 10(9):525-534. PubMed ID: 28701332
[TBL] [Abstract][Full Text] [Related]
25. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
Christoph F; König F; Lebentrau S; Jandrig B; Krause H; Strenziok R; Schostak M
World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy effectively suppresses interleukin-20, receptor activator of nuclear factor kappa-B ligand, and osteoprotegerin levels in patients with lung adenocarcinoma and bone metastasis.
Yu M; Su Y; Cui D; Sun Q; Luan B; Zhao D
J Cancer Res Ther; 2016; 12(2):963-8. PubMed ID: 27461682
[TBL] [Abstract][Full Text] [Related]
27. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.
Santini D; Schiavon G; Vincenzi B; Gaeta L; Pantano F; Russo A; Ortega C; Porta C; Galluzzo S; Armento G; La Verde N; Caroti C; Treilleux I; Ruggiero A; Perrone G; Addeo R; Clezardin P; Muda AO; Tonini G
PLoS One; 2011 Apr; 6(4):e19234. PubMed ID: 21559440
[TBL] [Abstract][Full Text] [Related]
28. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
[TBL] [Abstract][Full Text] [Related]
29. The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.
Omar HS; Shaker OG; Nassar YH; Marzouk SA; ElMarzouky MS
Mol Cell Biochem; 2015 May; 403(1-2):219-29. PubMed ID: 25724681
[TBL] [Abstract][Full Text] [Related]
30. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
31. Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease.
Sood SK; Balasubramanian S; Higham S; Fernando M; Harrison B
World J Surg; 2011 Sep; 35(9):1984-92. PubMed ID: 21748518
[TBL] [Abstract][Full Text] [Related]
32. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
33. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
[TBL] [Abstract][Full Text] [Related]
34. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
35. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
[TBL] [Abstract][Full Text] [Related]
36. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
[TBL] [Abstract][Full Text] [Related]
37. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
[TBL] [Abstract][Full Text] [Related]
38. Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases.
Todenhöfer T; Hennenlotter J; Schmiedel BJ; Hohneder A; Grimm S; Kühs U; Salih HR; Bühring HJ; Fehm T; Gakis G; Blumenstock G; Aufderklamm S; Schilling D; Stenzl A; Schwentner C
Prostate; 2013 Jan; 73(2):162-8. PubMed ID: 22715006
[TBL] [Abstract][Full Text] [Related]
39. Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH).
Pereira RMR; Figueiredo CP; Cha CC; Caparbo VF; Oliveira RM; Franco AS; Menezes PR; de Castro I; Onuchic LF
Osteoporos Int; 2016 Nov; 27(11):3319-3329. PubMed ID: 27311721
[TBL] [Abstract][Full Text] [Related]
40. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
Sarink D; Schock H; Johnson T; Chang-Claude J; Overvad K; Olsen A; Tjønneland A; Arveux P; Fournier A; Kvaskoff M; Boeing H; Karakatsani A; Trichopoulou A; La Vecchia C; Masala G; Agnoli C; Panico S; Tumino R; Sacerdote C; van Gils CH; Peeters PHM; Weiderpass E; Agudo A; Rodríguez-Barranco M; Huerta JM; Ardanaz E; Gil L; Kaw KT; Schmidt JA; Dossus L; His M; Aune D; Riboli E; Kaaks R; Fortner RT
BMC Cancer; 2018 Oct; 18(1):1010. PubMed ID: 30348163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
